BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
BioCryst (BCRX) Q1 2026: Orladeyo Revenue Jumps 21% as Pipeline Execution Accelerates
May 06, 2026
-
BioCryst (BCRX) Q4 2025: Orladeyo Revenue Jumps 43% as HAE Franchise Deepens Portfolio
February 26, 2026
-
BioCryst (BCRX) Q3 2025: Orladeyo Drives 37% Growth as Rare Disease Pipeline Expands
November 03, 2025
-
BioCryst (BCRX) Q2 2025: Orladeyo Surges 45% as U.S. Prescriber Base Expands
August 04, 2025
-
BioCryst (BCRX) Q1 2025: Paid Patient Rate Surges 10 Points, Accelerating Profitability Timeline
July 06, 2025
-
BioCryst (BCRX) Q3 2024: Orladeyo Grows 36% as Paid Rate Rises to 74.8%, Pushing Toward Profitability
November 04, 2024
-
BioCryst (BCRX) Q2 2024: Orladeyo Nears 20% U.S. Market Share as Paid Patient Base Hits 82% in Commercial Segment
August 05, 2024
-
BioCryst (BCRX) Q1 2024: Orladeyo Revenue Jumps 30% as Pipeline Readies for Clinical Expansion
May 06, 2024
-
BioCryst (BCRX) Q4 2023: Orladeyo Patient Base Surges by 321, Underscoring Durable Growth Path
February 26, 2024